iRadimed Posts Record Q4 2025 Revenue, Plans Europe and Asia Expansion
iRadimed posted record Q4 2025 revenue, surpassing its internal guidance and previous-year quarter, fueled by increased sales of its MR-compatible infusion pumps. The company outlined strategic growth initiatives including expanded distribution in Europe and Asia and heightened R&D investment for next-generation device development.
1. Record Q4 2025 Revenue
iRadimed delivered a new quarterly revenue high in Q4 2025, exceeding both its own guidance and the prior-year period. Strong demand for its MR-compatible infusion pumps, particularly in hospital MRI suites, drove the performance.
2. Strategic International Expansion
Management announced new distribution agreements in key European and Asian markets to broaden its global footprint. The company is also boosting R&D funding to accelerate development of next-generation infusion devices and support long-term growth.